Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Transplantation and Cellular Therapy
|
June 6, 2022
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
Geoffrey D E Cuvelier, Michelle Schoettler, Nataliya P Buxbaum, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
The New England Journal of Medicine
|
September 28, 2022
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Journal for Immunotherapy of Cancer
|
July 20, 2021
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, et al.
Acta Neuropathologica
|
September 12, 2025
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors
Subhiksha Nandakumar, Miika Mehine, Yelena Kemel, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Transplantation and Cellular Therapy
|
June 6, 2022
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
Geoffrey D E Cuvelier, Michelle Schoettler, Nataliya P Buxbaum, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
The New England Journal of Medicine
|
September 28, 2022
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Journal for Immunotherapy of Cancer
|
July 20, 2021
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, et al.
Acta Neuropathologica
|
September 12, 2025
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors
Subhiksha Nandakumar, Miika Mehine, Yelena Kemel, et al.
Page
of 5